

## Acute Kidney Injury in the spotlight at the world's largest international cardiovascular conference TCT 2018

### Highlights:

- Osprey Medical showcased at the 30<sup>th</sup> Transcatheter Cardiovascular Therapeutics (TCT) conference with two scientific sessions and moderated abstract sessions focused on awareness and prevention of contrast induced Acute Kidney Injury (AKI)
- Osprey Medical featured its Be Kind to Kidneys™ Program, patient education materials and GE partnership at its tradeshow booth in the exhibit hall

**26 September 2018 – Melbourne, Australia – Osprey Medical (ASX: OSP)** today celebrates the extensive attention delivered to Chronic Kidney Disease (CKD) and AKI at the 30<sup>th</sup> TCT conference in San Diego, California. The TCT is the world's largest and most important educational meeting specialising in interventional cardiovascular and vascular medicine. TCT has been the center of cutting-edge educational content, showcasing the latest advances in current therapies and clinical research.

At TCT's scientific lunch symposium, CI-AKI: Preventive Measures That Work, three of the presentations focused on the importance of contrast minimization to reduce the risk of AKI. The key presentations included: *"Renal Function Contrast Media Dosing in High Risk Patient Populations"* (Dr. Hitinder Gurm), *"Development of a Kidney Care Protocol in the Cath Lab: Screening, Hydration, and Dye Minimization"* (Dr. Vishal Gupta), *"Effect of MARCE Incidence and Economic Impact Resulting From Contrast Media Use in the Cath Lab"* (Dr. Emmanouil Brilakis).

A continuing medical education accredited Hot Topic Session, "Focus on Chronic Kidney Disease and Contrast Nephropathy", provided a comprehensive overview of AKI prevention strategies and managing special clinical scenarios in patients at risk for AKI. Additionally, two moderated poster sessions were dedicated to treatment methods for CKD patients in Chronic Total Occlusions, Percutaneous Coronary Interventions, and Transcatheter Valvular procedures. All of these sessions analyzed the unique risks associated with treating CKD patients in the Cath Lab, shared clinical studies detailing poor clinical outcomes of patients who acquire AKI, and provided assessments on how best to reduce the risk of AKI in CKD patients.

Osprey Medical featured its *Be Kind to Kidney™* program at its tradeshow booth with messaging focused on creating awareness and education of the clinical society guidelines to Screen, Hydrate, and Reduce Contrast when treating high-risk patients. Osprey showcased its DyeVert™ Plus Contrast Reduction System highlighting the growing clinical experience that use of the DyeVert System consistently reduces the amount of contrast delivered to patients by 40%<sup>1</sup> while maintaining image quality. Newly published research from Dr. Gurm was socialized, detailing ultra-low contrast (dye) volume strategies which resulted in significant reduction in AKI, or the need for dialysis<sup>2</sup>.

Osprey Medical's President and CEO, Mike McCormick, said: "This was a very successful TCT for Osprey Medical and provided us with high exposure to the physicians who are ultimately the end users of our one of a kind technology. Dye reduction strategies need to be a core part of best practices in the Cath Lab as excess dye has been shown to have negative near and long-term outcomes for patients with vulnerable kidneys. The DyeVert Plus system is designed to address this exact problem and be part of a comprehensive kidney care protocol in the Cath Lab."

## References:

1. Desch, et al. Impact of a novel contrast reduction system on contrast savings in coronary angiography – The DyeVert randomised controlled trial, Int J Cardiol (2018); [https://www.internationaljournalofcardiology.com/article/S0167-5273\(17\)35968-5/fulltext](https://www.internationaljournalofcardiology.com/article/S0167-5273(17)35968-5/fulltext)
2. Gurm, et. al. Contemporary use of outcomes associated with ultra-low contrast volume in patients undergoing percutaneous coronary interventions. Catheter Cardiovasc Interv (2018); DOI: 10.1002/ccd.27819

## Contact details:

### Media

Andrew Hamilton  
Mana Communications  
T: (61) 420 447 669  
[ah@manacomunications.com](mailto:ah@manacomunications.com)

### Investors

Kyahn Williamson  
Buchan Consulting  
M: (61) 401 018 828  
[kwilliamson@we-buchan.com](mailto:kwilliamson@we-buchan.com)

### Company

Doug Schoenberg  
VP of Marketing  
T: (952) 955 8230  
[dschoenberg@ospreymed.com](mailto:dschoenberg@ospreymed.com)

## About Osprey

Osprey Medical's vision is to make heart imaging procedures safer for patients with poor kidney function. The amount of dye (contrast) used during angiographic imaging procedures increases the patient's risk for dye-related kidney damage known as Contrast Induced Acute Kidney Injury (AKI). The Company's core technologies originated from research conducted by Dr David Kaye at Melbourne's Baker Institute. Its proprietary dye reduction and monitoring technologies are designed to help physicians minimize dye usage and monitor the dose of dye real time throughout the procedure. The Company's DyeVert™ Plus System reduces contrast while maintaining image quality in a self-adjusting easy-to-use design that monitors dye usage. Osprey Medical's Board and Management are comprised of experienced and successful personnel with established track records covering medical device development, regulatory approvals, sales and marketing, and mergers-acquisitions. Osprey Medical's advisory board comprises world-recognised experts in heart and kidney diseases.

## Forward-Looking Statements

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position. Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Osprey does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Osprey may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

## Foreign Ownership Restriction

Osprey's CHES Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of Osprey's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.